MTRF1

Across TCGA pan-cancer cohorts, MTRF1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MTRF1 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MTRF1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTRF1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where MTRF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.824	0.626	.004	12	view →
HNSC	DFS	Median	III,IV	0.887	1.000	.009	9	view →
LSCC	DFS	Tertile	All	0.495	1.000	.012	5	view →
UCEC	OS	Median	III,IV	0.311	1.000	.013	4	view →
GBM	DFS	Median	All	0.813	0.626	.040	2	view →
LUAD	OS	Median	All	0.948	1.000	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MTRF1–CCRCC (DFS)

Open the CCRCC breakdown →